Mar 17, 2021 / NTS GMT
RenéC. Goehrum - BioSyent Inc. - Chairman, CEO & President
Hello. Welcome to the BioSyent Inc. Q4 and Fiscal Year 2020 Results Presentation. My name is René Goehrum, and I'm the President and CEO of the company.
I'm going to start the presentation with a look at our sales, EBITDA and net income after tax for the quarter ended December 31, 2020. So this quarter represented our 42nd consecutive profitable quarter. Our sales were up 3% in the quarter to the year ago, reaching $5.72 million, and that was made up with a few puts and takes. On the put side, the Canadian pharmaceutical business was up 7% in dollars versus the year ago, and the legacy business was up 180% versus the year ago. But remarkably as well, our international pharmaceutical business was down 87% in the quarter. The net-net of all those puts and takes was growth of 3% corporately.
On the income side, we had impacts of significant investment in growth assets. So we've been launching 3 products, namely Tibella, Combogesic and FeraMAX Pd. And as a group, we've invested just under $700,000 in those 3 assets
Q4 2020 Biosyent Inc Earnings Call Transcript
Mar 17, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers